()
 
 

Overview

La Jolla, CA-headquartered Immunosyn Corporation (OTC Bulletin Board: IMYN - News) plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the US and Europe. Research suggests that SF-1019 has the potential to affect a number of clinical conditions including auto-immune disorders such as Multiple Sclerosis (MS), neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS) and complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and Diabetic Ulcers (DU).


Contact Information

4225 Executive Square
Suite 260
La Jolla, CA 92037

tel: 858-200-2320
fax:


,  



Investor Relations



tel:
fax:




Stock

Exchange: OTCBB
Industry: Unknown
Market Cap: $775.2M




 
The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.